



YOUNGSTOWN STATE UNIVERSITY

# HCAC MEETING

February 15, 2024

[www.usi.com](http://www.usi.com)

# Agenda

---

- Financial Reporting
- USI 3D (Data Analytics) Selected Charts
- 7.1.24 Cost Projection Review


---

# Financials

## YSU Rolling 12 Month Executive Summary (Medical and Pharmacy)

Experience Period	2/1/22-1/31/23	2/1/23-1/31/24	Change
Average Enrollment	913	893	-2.18%
Medical Claims	\$15,592,094	\$12,187,258	-21.84%
Rx Claims	\$3,568,664	\$4,165,164	16.71%
Subtotal Plan Gross Claim Costs	\$19,160,758	\$16,352,422	-14.66%
Fixed costs (Fees and Stop Loss)	\$2,276,831	\$2,429,492	6.70%
Total Plan Gross Costs	\$21,437,589	\$18,781,914	-12.39%
Total Plan Gross Costs (PEPM*)	\$1,957.23	\$1,753.03	
Gross Cost Increase from Prior Year		<b>-10.43%</b>	
Stop Loss Reimbursement	(\$3,592,528)	(\$1,600,266)	-55.46%
Total Plan Net Costs (Gross Costs Less Reimbursement)	\$17,845,061	\$17,181,648	-3.72%
Total Plan Net Costs (PEPM*)	\$1,629.24	\$1,603.66	
Net Cost Increase from Prior Year	-	<b>-1.57%</b>	
<i>*Per Employee Per Month</i>			
7/1/18 Med/Rx renewal			+5.49%
7/1/19 Med/Rx renewal			+8.66%
7/1/20 Med/Rx renewal			+8.96%
7/1/21 Med/RX renewal			+5.76%
7/1/22 Med/RX renewal			+4.45% and Plan changes
7/1/23 Med/Rx renewal			+8.52% - Stop Loss Change


# Youngstown State University Gross Medical and Prescription Drug Claims and Fixed Costs (PEPM)





Youngstown State University  
Medical/Rx Plan - Medical Mutual  
Large Claimant Report  
Plan Year to Date (Data through January 2024)

≥ \$100,000 Large Claimants as a % of Total Claims



Category	Total (\$)	% of Total
Claims > \$250k	1,965,096	19.5%
Claims \$175k-\$250k	603,115	6.0%
Claims \$100k-\$175k	1,108,572	11.0%
All Other Claims <\$100k	6,383,235	63.5%
<b>Total</b>	<b>10,060,018</b>	<b>100.0%</b>

Paid Claims > \$100,000

Diagnosis	Relationship	Status	Medical Claims	Rx Claims	Total Amount	Claims Over SSL (\$)
1 ENCOUNTER FOR OTHER AFTERCARE	EE	ACTIVE	480,648	4,131	484,779	234,779
2 CANCER: MERKEL CELL CARCINOMA	EE	ACTIVE	430,679	1,324	432,003	182,003
3 OTHER PULMONARY HEART DISEASES	EE	ACTIVE	2,455	417,922	420,376	170,376
4 ENCOUNTER FOR OTHER AFTERCARE	SP	ACTIVE	337,744	3,738	341,482	91,482
5 MALNUTRITION: UNSPECIFIED SEVERE PROTEIN-CALORIE MALNUTRITION	EE	ACTIVE	286,455	-	286,455	36,455
6 GASTRITIS AND DUODENITIS	DEP	ACTIVE	19,065	206,223	225,288	-
7 CANCER: KIDNEY	DEP	ACTIVE	193,223	116	193,339	-
8 OTHER DISEASES OF THE PANCREAS	EE	CANCEL	170,850	13,639	184,488	-
9 OTHER SEPSIS (BLOOD INFECTIONS)	EE	CANCEL	159,756	46	159,802	-
10 EPILEPSY AND RECURRENT SEIZURES	DEP	ACTIVE	139,732	5,097	144,829	-
11 INJURY OF URINARY AND PELVIC ORGANS	EE	ACTIVE	137,862	689	138,551	-
12 ENCOUNTER FOR OTHER AFTERCARE	EE	ACTIVE	119,436	83	119,520	-
13 COMPLICATIONS OF PROCEDURES NOT ELSEWHERE CLASSIFIED	EE	ACTIVE	10,446	102,313	112,760	-
14 DISLOCATION AND SPRAIN OF JOINT AND LIGAMENTS AT NECK LEVEL	DEP	ACTIVE	110,782	-	110,782	-
15 CELLULITIS AND ACUTE LYMPHANGITIS	SP	ACTIVE	88,094	20,742	108,836	-
16 CROHN'S DISEASE (REGIONAL ENTERITIS)	EE	ACTIVE	65,586	41,479	107,065	-
17 ENTHESOPATHIES (MUSCLE TENDON, LIGAMENT DISORDER), LOWER LIMB, EXCLUDING FOOT	SP	ACTIVE	210	106,218	106,428	-
<b>Total</b>			<b>2,753,022</b>	<b>923,761</b>	<b>3,676,783</b>	<b>715,096</b>

Notes

1. Specific stop loss is \$250,000.

# Youngstown State University

## Medical and Prescription Drug Large Claims Summary (FY Comparison)

Claimants	2023/2024 Plan Year (7/1/23-1/31/24)				2022/2023 Plan Year (7/1/22-1/31/23)			
	Status	Medical	Rx	Total	Status	Medical	Rx	Total
Claimant #1	ACTIVE	\$480,648	\$4,131	\$484,779	ACTIVE	\$613,870	\$4,312	\$618,182
Claimant #2	ACTIVE	\$430,679	\$1,324	\$432,003	CANCEL	\$391,140	\$5,020	\$396,159
Claimant #3	ACTIVE	\$2,455	\$417,922	\$420,377	ACTIVE	\$371,314	\$22,365	\$393,679
Claimant #4	ACTIVE	\$337,744	\$3,738	\$341,482	ACTIVE	\$10,451	\$358,561	\$369,012
Claimant #5	ACTIVE	\$286,455	\$0	\$286,455	CANCEL	\$335,479	\$527	\$336,005
Claimant #6	ACTIVE	\$19,065	\$206,223	\$225,288	ACTIVE	\$318,178	\$27	\$318,204
Claimant #7	ACTIVE	\$193,223	\$116	\$193,339	ACTIVE	\$227,652	\$103	\$227,756
Claimant #8	CANCEL	\$170,850	\$13,639	\$184,489	ACTIVE	\$174,329	\$4,098	\$178,427
Claimant #9	CANCEL	\$159,756	\$46	\$159,802	ACTIVE	\$157,704	\$592	\$158,296
Claimant #10	ACTIVE	\$139,732	\$5,097	\$144,829	ACTIVE	\$7,600	\$138,814	\$146,415
Claimant #11	ACTIVE	\$137,862	\$689	\$138,551	ACTIVE	\$64,181	\$66,248	\$130,429
Claimant #12	ACTIVE	\$119,436	\$83	\$119,519	CANCEL	\$127,738	\$363	\$128,101
Claimant #13	ACTIVE	\$10,446	\$102,313	\$112,759	ACTIVE	\$3,032	\$107,260	\$110,292
Claimant #14	ACTIVE	\$110,782	\$0	\$110,782	ACTIVE	\$101,279	\$72	\$101,351
Claimant #15	ACTIVE	\$88,094	\$20,742	\$108,836				
Claimant #16	ACTIVE	\$65,586	\$41,479	\$107,065				
Claimant #17	ACTIVE	\$210	\$106,218	\$106,428				
Claimant #18								
Claimant #19								
Claimant #20								
Claimant #21								
Claimant #22								
Claimant #23								
Claimant #24								
Claimant #25								
Claimant #26								
Claimant #27								
Claimant #28								
Claimant #29								
Claimant #30								
Claimant #31								
Claimant #32								
Total Medical and Rx Claims > \$100,000		\$3,676,783				\$3,612,309		
Total Claims in Excess of \$225,000 Specific Stop Loss - eff 7.1.18		(\$715,096)				(\$1,083,998)		
Net Large Claims		\$2,961,687				\$2,528,311		
Total Medical and Rx Claims		\$10,060,018				\$10,435,032		
Average Medical Claims > \$100,000		\$216,281				\$258,022		
NET Claims > \$100,000 as a % of Total Medical and Rx Claims		29.44%				24.23%		


Denotes, these members were on the report in the prior year as well

---

# USI 3D Selected Charts




## Top Chronic Diseases




- In areas where your claims experience exceeds norm, chronic condition management may be beneficial.

# Quality Risk Measurements

## Most Compliant Standards in Care Compared to Norms



## Least Compliant Standards in Care Compared to Norms



- Most Compliant and least Compliant is based on your group's performance against USI Book of Business norms.
- USI BOB is a reference but not a goal. Group specific goals should be used to show improved compliance over time using communication strategy, solutions or plan design changes.
- Members not receiving essential testing can lead to future health and cost risk.

# Top Drugs by Cost and Prevalence











Top Drugs by Paid Claims

Top Rx	Total Paid	Script Count	Unique Users
STELARA	\$432,225	20	3
UPTRAVI	\$372,127	24	1
VERZENIO	\$141,668	10	1
ADEMPAS	\$139,459	11	1
OPSUMIT	\$139,320	12	1
LENALIDOMIDE	\$134,600	9	1
JARDIANCE	\$119,576	87	21
TRULICITY	\$114,687	51	12
OZEMPIC	\$109,971	58	16
LENVIMA	\$86,416	4	1

Top Drugs by Unique Members

Top Rx	Total Paid	Script Count	Unique Users
AMOXICILLIN	\$1,917	391	281
METHYLPREDNISOLONE	\$3,103	323	237
AZITHROMYCIN	\$1,527	287	214
AMOXICILLIN-CLAVULANATE POTASS	\$2,153	238	193
PREDNISONE	\$1,195	279	174
FLUCELVAX QUAD 2023-2024	\$7,114	160	160
FLUTICASONE PROPIONATE	\$2,577	301	147
ATORVASTATIN CALCIUM	\$6,457	627	146
DOXYCYCLINE HYCLATE	\$1,203	194	141
LEVOTHYROXINE SODIUM	\$4,374	437	138

- These drugs represent 45.1% of your total prescription drug cost, which is \$3,966,418.
- Some high cost drugs can be managed via specialty drug programs.
- These drugs are indicative of some of the most common conditions which correspond to the Top Diagnostic Groups chart in this report.
- Percent Generic Utilization in current time period was 85.9% and prior time period was 83.9%. Optimal Generic Dispensing rate is 89%.

		Your Performance is indicated by 	Savings Potential
Strategy: Plan Design Changes		0255075100	
	High Level KPI: Prescription Drug Claims as a % of All Paid Claims [Rx / (Med + Rx)]	21.6% 	N/A
	Generic Dispensing Rate (GDR): Percentage of Total Scripts filled as Generic	86.0% 	\$169,391
	Retail 90 & Mail Order for Chronic Condition Patients: % of Scripts Filled via Retail 90 and/or Mail Order	55.9% 	\$28,862
Strategy: Formulary Changes			
	Wasteful Drug Spending: Percentage of Paid Claims on High Cost, Low Value Drugs	0.6% 	\$18,308
	Formulary Maximization: Non-formulary Utilization as a % of Total Scripts	5.6% 	\$379,998
Strategy: Programs focusing on Improving Specialty Drug Spending			
	High Level KPI: Specialty Paid as a Percent of Total Pharmacy Paid	47.9% 	N/A
	Patient Assistance Program (PAP): Percentage of Rx Paid Claims that are potentially PAP-eligible	15.6% 	\$448,957
	High Level KPI : Medical “J-code” Drugs and Injectables as a % of Total Paid Claims (Med + Rx)	10.6% 	N/A
	Gene/Cell Therapy Exposure: Diagnoses with potential for future Gene/Cell Therapy claims (Low = 0, Moderate = 1-5, High = 6+)		High Exposure
	Hemophilia Alternatives: Paid Claims towards Hemophilia Drugs as a % of Total Rx Paid Claims	0.0% 	\$0
Total Savings Potential Across Medical and Drug Claims:			\$1,045,516

---

## 7.1.24 Cost Projection

# 7/1/24 Preliminary Funding Discussion

---

- Recall, 7/1 Projections are finalized using 24 months of claims data, ending March 31 of each year
- 7/1/18 Renewal Action: +5.49%
- 7/1/19 Renewal Action: +8.66%
- 7/1/20 Renewal: +8.96%
- 7/1/21 Renewal: +5.76%
- 7/1/22 Renewal: +4.45% with plan changes
- 7/1/23 Renewal: +8.52%

# 7/1/24 Preliminary Funding Discussion

---

- Actuarial Evaluation
  - 24 months of claims from 4/1/22-3/31/24
  - 24 months of large claims
  - Apply any plan design changes
  - Apply Trend Factors – Health care inflation
  - Apply 3.75% claims fluctuation corridor
  - Add in ASO administrative fees and other fixed expenses
  - Estimated Stop Loss renewal
  - Compare to current funding (rates set as of 7/1/23)
  - Early Estimates (M/Rx): 6-8% (data through January of 2024)

# Preliminary 7/1/24 Rate Timeline

---

- Review preliminary projections with HCAC in February
- USI will continue to update projections with February and March data once available
- Renewal from MMO not released yet
- Once MMO renewal is in hand, USI to evaluate and negotiate and provide final underwriting evaluation to YSU and HCAC.